drugset / Trial / NCT00730691

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00730691

Phase 3 Completed 781 enrolled Takeda H. Lundbeck A/S · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.

Timeline

Start
2008-06
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Subject Vortioxetine Unknown 2.5 mg Oral
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral